3205-37-6

Usage

Structure

Cyclohexane ring with two acetonitrile groups attached in a specific stereochemical arrangement.

Stereochemistry

(1S,2S)configuration, indicating the orientation of the acetonitrile groups on the cyclohexane ring.

Functional Groups

Acetonitrile groups (CN) attached to the cyclohexane ring.

Application

Used in organic synthesis as a building block for the production of various pharmaceuticals, agrochemicals, and other fine chemicals.

Intermediate

Commonly utilized as an intermediate in the synthesis of various chiral compounds due to its unique stereochemical properties.

Versatility

Serves as a versatile starting material for the preparation of diverse organic molecules.

Importance

A valuable tool in the field of organic chemistry due to its wide range of applications and stereochemical properties.

Upstream product

• 66347-68-0 (±)-(1S, 2S)-cyclohexane-1,2-dimethanol bis(methanesulfonate) 
• 76155-27-6 (+/-)-trans-2-(hydroxymethyl)cyclohexylmethanol 
• 3205-36-5 trans-1,2-bis(hydroxymethyl)cyclohexane di-p-toluene-sulfonate 

Downstream Products

• 959009-59-7 (3aS,7aR)-2-Amino-3a,4,5,6,7,7a-hexahydro-3H-indene-1-carbonitrile 
• 40599-78-8 trans-cyclohexane-1,2-diacetic acid 

Relevant academic research and scientific papers

Discovery of octahydroindenes as PAR1 antagonists

Octahydroindene was identified as a novel scaffold for protease activated receptor 1 (PAR1) antagonists. Herein, the 2-position (C2) was explored for structure-activity relationship (SAR) studies. Compounds 14, 19, and 23b showed IC50 values of 1.3, 8.6, and 2.7 nM in a PAR1 radioligand binding assay, respectively, and their inhibitory activities on platelet activation were comparable to that of vorapaxar in a platelet rich plasma (PRP) aggregation assay. This series of compounds showed high potency and no significant cytotoxicity; however, the compounds were metabolically unstable in both human and rat liver microsomes. Current research efforts are focused on optimizing the compounds to improve metabolic stability and physicochemical properties as well as potency.

[6+5] FUSED BICYCLES AS A THROMBIN ANTAGONIST, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE BICYCLES

The present invention relates to the new [6+5] fused bicycle derivatives, pharmaceutically acceptable salts or isomers thereof, processes for preparing the same, and pharmaceutical compositions comprising the same. The [6+5] fused bicycle derivatives can antagonize the thrombin receptor and thus may be effectively used for the treatment and prevention of thrombus, platelet aggregation, atherosclerosis, restenosis, blood coagulation, hypertension, arrhythmia, angina pectoris, heart failure, inflammation and cancer when used alone or with other cardiovascular agents.